Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age \>= 40 years;~2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years;~3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF~4. Dlco (corrected for Hb): 30%-79% predicted of normal;~5. FVC\>= 50% predicted of normal~Exclusion criteria:~1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \> 1.5 x Upper Limit of Normal (ULN)~2. Bilirubin \> 1.5 x ULN;~3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC \< 0.7);~4. Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation);~5. Myocardial infarction within 6 months;~6. Unstable angina within 1 month;~7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or ulcers or major injury or surgery within 3 months);~8. Thrombotic risk (inherited predisposition; history of thrombotic event (including stroke and transient ischemic attacks) within 12 months;~9. International normalised ratio (INR) \> 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by \> 50% of institutional ULN);~10. N-ACetyl Cystein, prednisone \> 15mg/day or equivalent received within 2 weeks of visit 1;~11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of visit 1;

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBF 1120 (Type: EXPERIMENTAL): patient receives capsules containing BIBF 1120 twice a day
- placebo (Type: PLACEBO_COMPARATOR): patient receives capsules identical to those containing active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).